2333 GMT - Licensing income from the Daybue treatment for Rett Syndrome alone supports Neuren Pharmaceuticals's share price, meaning investors effectively get exposure to its next drug candidate "for free," Bell Potter says. Neuren is upbeat about the potential of NNZ-2591 as a treatment of several neurodevelopmental disorders. It has cited positive results from Phase 2 clinical trials in Phelan-McDermid syndrome, Pitt Hopkins syndrome and Angelman syndrome. Still, Bell Potter says it will be two years until Neuren's next major clinical catalyst: the first Phase 3 trial results for NNZ-2591. "Neuren has unrivalled balance sheet strength to prosecute future NNZ-2591 development yet effectively zero value is currently attributed to this asset, likely due to the Phase 3 readout timing," analyst Thomas Wakim says. Bell Potter retains a "buy" call on Neuren. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
March 11, 2025 19:33 ET (23:33 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。